The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC)—An open-label multicenter phase 2 study.
 
Virginia Kaklamani
Honoraria - AstraZeneca; daichi; Genentech; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly; Menarini; Puma Biotechnology; tersera; tersera
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer
Research Funding - Eisai
 
Giorgi Dzagnidze
No Relationships to Disclose
 
Nicoleta Antone
No Relationships to Disclose
 
Anu Thummala
Honoraria - daichii sankyo; daichii sankyo
Speakers' Bureau - Daichii Sankyo
Travel, Accommodations, Expenses - mckesson/usoncology (Inst)
 
Mikheil Janjalia
No Relationships to Disclose
 
Patricia Santi
No Relationships to Disclose
 
Carlos Barrios
Stock and Other Ownership Interests - CPO; MedSIR; Thummi
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Aveo (Inst); BioNTech SE (Inst); BMS Brazil (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Exelixis (Inst); Exelixis (Inst); FORTREA (Inst); FORTREA (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ICON Clinical Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Samsung (Inst); Sandoz (Inst); Sanofi (Inst); Servier (Inst); Sremline (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Mehmet Sendur
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abdi Ibrahim; Abdi Ibrahim; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
 
Xiaoling Zhang
Employment - Menarini Group
 
Angela Gambioli
Employment - Menarini Group
 
Manuel Domínguez Lizarbe
Employment - Menarini
 
Kathy Theall
Employment - Menarini Group
 
Tomer Wasserman
Employment - Menarini Group
 
William Gradishar
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Gilead Sciences; merck; Novartis; Pfizer